As part of Itchy Pet Awareness Month, Zoetis announced on Aug. 15 the 10 nonprofit pet shelters and rescues across the U.S. that will receive Apoquel grants for providing relief from allergic dermatitis to at least 100 dogs in each of their local communities. The grant program is part of Zoetis’ commemoration of the 10th anniversary of Apoquel, the most prescribed medicine for effective relief of allergic itch and inflammation in dogs due to atopic and allergic dermatitis.
All shelters enrolled in the Zoetis for Shelters program by June 2023 were considered for these grants if they had an annual intake of at least 100 dogs. Shelters were selected at random from the full list that met those criteria.
The following 10 nonprofit organizations have been selected as grant recipients:
One of the recipients, Connecticut Humane Society, the leading resource in the state for companion animal welfare, facilitates about 2,000 adoptions annually. Its team also conducts nearly 12,000 pet wellness exams for owned and surrendered animals.
“Every day, pets come through our doors and often, it’s as a last resort, when their families have nowhere else to turn," said James Bias, executive director of Connecticut Humane Society. “Our commitment is to give pets in need the love, and expert veterinary care they need until their next chapter starts, and this Apoquel grant helps us do exactly that.”
Another grant recipient, The Rescue Ranch, located in McRae, Georgia, focuses on providing animal rescue, spay and neuter services and pet health education to rural, underserved counties across the state.
“In the counties we serve, we see many dogs with untreated allergic itch, which makes it difficult for them to be adopted” said Barbara B, president of The Rescue Ranch, Inc. “There are no words for how life-changing an Apoquel grant like this will be for the itchy dogs in our care.”
Andrew Hillier, director of specialty and dermatology strategy for U.S. Petcare at Zoetis, said in a news release that the grants underscore the exceptional innovation that Zoetis has built in the veterinary dermatology space over the past decade.
“As we continue to reflect on a decade of groundbreaking advancements in canine dermatology, there’s no better time to emphasize our commitment to enhancing the well-being of the pets that bring such joy, enrichment and wellness to the lives of their human companions,” he said.
Apoquel has revolutionized the field of canine dermatology, offering veterinarians an innovative, first-of-its-kind treatment option for fast relief from allergic itch – a condition often marked by excessive scratching, chewing and licking in dogs. Veterinarians have now prescribed Apoquel to more than 13 million dogs, and it is the no. 1 oral medication in dog owner and vet satisfaction for allergic dermatitis.
About Apoquel
Do not use Apoquel in dogs less than 12 months of age or those with serious infections. Apoquel may increase the chances of developing serious infections and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel has been used safely with many common medications including parasiticides, antibiotics and vaccines.
Indications
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com
List
Add
Please enter a comment